Categories: NewsSeniors

HoneyNaps actively supplies “AI solutions” to U.S. medical institutions

  • Rapid commercialization and delivery to the U.S. after FDA approval
  • Aiming to achieve a 10% market share within three years
  • Aggressive sales and expansion of distribution network through U.S. subsidiaries

BOSTON, Oct. 7, 2024 /PRNewswire/ — HoneyNaps announced on September 9th that it has officially begun exporting by delivering its artificial intelligence sleep disorder diagnostic software “SOMNUM” to two medical institutions in the U.S.

The SOMNUM solution supplied to the U.S. is the third globally to receive approval from the U.S. Food and Drug Administration(FDA) in 2023. It is not just a system for interpreting biometric signal images, but a deep learning-based AI interpretation system capable of real-time analysis of multi-channel/temporal and large-scale biometric signals, developed using the world’s first explainable medical AI (XAI, eXplainable AI) technology.

The SOMNUM solution will be introduced into research on sleep health for seniors and the verification of sleep improvement programs. HoneyNaps has signed a licensing agreement based on annual usage fees for the software.

HoneyNaps is currently strengthening its B2B business with major companies in South Korea while simultaneously focusing on local sales through its U.S. subsidiary in Boston and its West Coast dealer channels, expecting continuous growth in export volume.

A HoneyNaps representative said, “The U.S. is the largest sleep medicine market in the world and still holds significant growth potential. As we officially enter the U.S. market, we will solidify our business strategy to achieve a 10% market share within three years.”

For further information, please contact:
HoneyNaps USA, Inc.
Christine Kwon / Managing Director
Email: sleep@honeynaps.com
Address: #517, 5th Fl., 361 Newbury Street, Boston, MA 02115
Website: www.honeynaps.com

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/honeynaps-actively-supplies-ai-solutions-to-us-medical-institutions-302268307.html

SOURCE HoneyNaps

Staff

Recent Posts

Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

Clinical trial infrastructure fully operational in the U.S. with more than 15 leading cardiovascular centers…

60 minutes ago

CannaPharmaRX Provides Corporate Update and Outlines Growth Strategy for 2026

CALGARY, AB / ACCESS Newswire / January 12, 2026 / CannaPharmaRX, Inc. (OTC PINK:CPMD), an…

12 hours ago

TempraMed Closes C$2.5 Million Fully Subscribed Private Placement

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE:…

15 hours ago

TruuCONNECT NJ Statewide Digital Hub Empowers Users to Find Verified, Local Community Resources and Support – Anonymously and in Real Time

MOUNT LAUREL, N.J., Jan. 12, 2026 /PRNewswire/ -- Born out of a partnership between the…

15 hours ago

Nuvo Unveils Large-Scale AI-Ready Pregnancy Dataset Built on Real-World Maternal and Fetal Physiology

Unique longitudinal dataset combining native fetal and maternal ECG with phonocardiography supports deeper insights into…

15 hours ago

Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer’s Disease Research

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision…

15 hours ago